市場調查報告書

全球膀胱癌治療及診斷市場 - 各種類、地區(2017年∼2022年)

Bladder Cancer Therapeutics and Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 353865
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
全球膀胱癌治療及診斷市場 - 各種類、地區(2017年∼2022年) Bladder Cancer Therapeutics and Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年05月01日內容資訊: 英文 115 Pages
簡介

膀胱癌,是在膀胱的表皮內層產生的泌尿系統的惡性腫瘤,是復發率最高,全球第9大癌症。過去10年膀胱癌治療有所發展,不過,還存在許多未滿足需求。膀胱癌治療及診斷市場,預計2015年從4億9,000萬美元以3%∼5%的年複合成長率穩定成長。

本報告提供全球膀胱癌治療及診斷市場相關調查,市場概要,各癌症類型、治療方法、診斷法、地區的市場趨勢,市場規模的變化與預測,市場成長、阻礙因素以及市場機會、課題分析,市場佔有率,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 市場定義
  • 調查方法
  • 對象市場

第2章 摘要整理

第3章 市場概要

  • 市場成長要素
    • 對膀胱疾病和其可利用的治療方法的意識高漲
    • 增加的醫療費用支出
    • 開發藥劑中創新和技術的進步
  • 市場阻礙因素
    • 專利到期數量的增加
    • 非專利醫藥品的使用增加
    • 無症狀性
  • 市場機會
  • 市場威脅

第4章 波特的五力分析

  • 買方議價能力
  • 供給企業談判力
  • 新加入業者的威脅
  • 替代品的威脅
  • 競爭企業間的敵對關係

第5章 市場區隔

  • 癌症各類型
    • 尿路表皮癌症
    • 表淺性膀胱癌
    • 浸潤性膀胱癌
    • 膀胱鱗狀細胞癌
    • 其他
  • 各治療法
    • 化療
    • 免疫療法
    • 放射線治療
    • 手術
  • 各診斷法
    • 膀胱鏡檢驗
    • 切片檢查
    • 尿液檢查
    • 尿細胞診斷
    • 超音波檢驗
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東、非洲

第6章 競爭情形

  • 合併、收購
  • 協定,合作,夥伴關係
  • 新產品的銷售
  • 對新加入企業的建議

第7章 企業簡介

  • Novartis International AG
  • Pfizer Inc
  • GlaxoSmithKline plc
  • Sanofi SA
  • Eli Lilly and Co
  • AstraZeneca plc
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche AG
  • Celgene Corporation

第8章 附錄

  • 簡稱
  • 參考資料
  • 參考文獻
  • 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 49086

Market Overview

The bladder cancer therapeutics and diagnostics market will show rapid growth due to increasing awareness about bladder diseases and available therapies, increasing healthcare expenditure and innovations in drug development. There has been a rapid increase in the overall healthcare expenditure globally over the past few years. Therefore there are new medical technologies, treatments, and medicines available for these bladder cancer diseases that contribute majorly in the overall rise in the healthcare costs. The high drug prices, drug patent expiry, and cost of healthcare services account for two-thirds of the rise in healthcare spending. The expenditure on increased services, which includes costs of labor and productivity (in biopharmaceutical industries) is also one of the major factors driving the healthcare costs.

In addition, the growing research in the development of innovative bladder cancer therapies and the presence of pipeline therapeutics are further propelling the growth of the bladder cancer therapeutics market. Furthermore, the rise in awareness about bladder cancer and their available therapies, growing smoking and tobacco consumption are also motivating the market.

Scope of the Report

As per the scope of the report, bladder cancer is a tumor, which starts in the cells of the bladder. Bladder cancer is the rapid, uncontrolled growth of abnormal cells in the urinary bladder lining with epithelial cells. These cancerous cells may even spread through the lining into the muscular wall of the bladder. At present, a number of therapies have evolved to treat bladder cancers, which in turn build a high demand for the bladder cancer therapeutics market.

Key Market Trends

Cystoscopy is Anticipated to be the Dominant Segment in Diagnostics during the Forecast Period

Cystoscopy is a procedure used to see the interiors of the bladder and urethra using a telescope. A cystoscope is a specialized endoscope that is inserted through the urethra into the bladder to allow direct visual inspection of the urothelium. Cystoscopy is thus cost-effective, though, in combination with other tests, the cost varies. There are approximately 1.2 million flexible cystoscopy procedures conducted annually in the United States, and thus the introduction of Cysview is boosting the growth of the market and is expected to record a higher growth rate, during the forecast period.

North America Region Holds the Largest Market Share of Bladder Therapeutics And Diagnostics Market

The ecosystem for research and development for drugs for cancer is well established in North America, particularly in the US. Additionally, the presence of a large number of biologics companies and biopharmaceutical companies is contributing to the large size and excellent growth of bladder cancer therapeutics and diagnostics market.

North America also has the best adoption rates of new diagnostic modalities that are introduced in commercial space. This trend is in contrast with other regions of the world where the most widely adopted technologies for cancer diagnostics are at least a decade old. Consequently, North America is a leader in terms of the market size in the global bladder therapeutics and diagnostics market.

Competitive Landscape

The major companies active in the market are AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, Epocrates, Genentech, GlaxoSmithKline, Roche, Merck & Co, Novartis, Pfizer and so on. The companies present in the market are found focusing on product innovations, expansions, finding new markets or innovating their core competency to expand their individual market share.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Awareness About Bladder Diseases and Available Therapies
    • 4.2.2 Increasing Healthcare Expenditure
    • 4.2.3 Innovations in Drug Development
  • 4.3 Market Restraints
    • 4.3.1 Rise in the Number of Patent Expirations
    • 4.3.2 Asymptomatic Nature of the Disease
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Cancer Type
    • 5.1.1 Transitional Cell Bladder Cancer
    • 5.1.2 Superficial Bladder Cancer
    • 5.1.3 Invasive Bladder Cancer
    • 5.1.4 Squamous Cell Bladder Cancer
    • 5.1.5 Other Rare Types
  • 5.2 By Therapeutics
    • 5.2.1 Chemotherapy
    • 5.2.2 Immunotherapy
    • 5.2.3 Radiation Therapy
    • 5.2.4 Surgery
  • 5.3 By Diagnostics
    • 5.3.1 Cystoscopy
    • 5.3.2 Biopsy
    • 5.3.3 Urinalysis
    • 5.3.4 Bladder Ultrasound
    • 5.3.5 Other Diagnostics
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Astra Zeneca Plc.
    • 6.1.2 Bristol Myers Squibb
    • 6.1.3 Celgene Corporation
    • 6.1.4 Eli Lilly and Co.
    • 6.1.5 GlaxoSmithKline Plc.
    • 6.1.6 F Hoffmann-La Roche AG
    • 6.1.7 Novartis International AG
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Sanofi S.A.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS